Synthetic blood market seen reaching $15.7B by 2030

The Business Research Company says the synthetic blood substitutes and blood products market will grow from $7.6 billion in 2025 to $15.7 billion by 2030, driven by blood shortages, more surgeries and rising demand for emergency-ready alternatives. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Synthetic blood substitutes and blood products are designed to replace or support key blood functions such as oxygen transport and clotting. - The products matter because they can help when donor blood is limited, transfusion risks are high, or patients need emergency care. - The market outlook signals growing demand tied to trauma care, surgery, chronic disease and military medicine.

What happened: - The Business Research Company published a market study on synthetic blood substitutes and blood products on Aug. 31, 2026. - The report estimates the market will rise from $7.6 billion in 2025 to $8.81 billion in 2026. - The study forecasts the market will reach $15.7 billion by 2030. - The report projects a 15.9% compound annual growth rate from 2025 to 2026. - The report projects a 15.6% compound annual growth rate from 2026 to 2030. - Download a free sample of the report. - View the full market report.

The details: - The 2025 to 2026 growth is linked to shortages in blood donations, higher demand from trauma and surgical procedures, concerns about transfusion-transmitted infections, more cardiovascular surgeries and military medicine needs. - The 2026 to 2030 growth is expected to come from more trauma cases, more surgeries among older adults, advances in recombinant factor technologies, demand for universal blood substitutes and higher spending on emergency preparedness. - The report points to key trends including oxygen-carrying blood substitutes, emergency trauma alternatives, less dependence on donor blood, longer shelf-life products and wider use in military and disaster medicine. - The report describes synthetic blood substitutes and blood products as biotechnological solutions that replicate functions of human blood. - The products are used to support oxygen delivery and clotting. - The products serve as alternatives to donor blood in shortages, emergencies and cases involving special medical needs. - The report says chronic disease prevalence is one of the main growth drivers. - The report cites data from the UK’s Office for Health Improvement & Disparities showing type 2 diabetes prevalence among adults in England rose to 7.0% in March 2024 from 6.8% the year before.

Between the lines: - The market forecast reflects a broader push to reduce reliance on donated blood and improve readiness for crises. - Emergency medicine, defense planning and aging populations are shaping demand at the same time. - The report’s focus on longer shelf life and universal substitutes suggests manufacturers are targeting logistical gaps as much as clinical ones.

What's next: - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated technology and trend analysis. - The Business Research Company invited readers to contact Saumya Sahay for more information.